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BACKGROUND: COPD is a high-mortality disease and projected to become the third leading
cause of death worldwide by 2030. Our aim was to evaluate predictors of 3-y mortality and factors
associated with early (1 y) and late (second and third year) mortality in subjects with severe COPD
who completed a pulmonary rehabilitation program. METHODS: A historical cohort study was
performed with subjects with COPD who were admitted to a day-hospital for chronic respiratory
failure for a pulmonary rehabilitation program, from January 2008 to December 2010. The pop-
ulation was characterized based on sociodemographic factors, body mass index, smoking habits,
lung function tests, respiratory failure, comorbidities, bacterial colonization, Modified Medical
Research Council dyspnea index, 6-min walk test, mechanical ventilation, noninvasive ventilation,
long-term oxygen therapy, hospital admissions, and mortality. RESULTS: From 183 patients who
completed a pulmonary rehabilitation program, 93 had COPD. Our cohort had 78 male and 15
female subjects. The mean age  SD was 68.6  8.9 y, ranging from 43 to 85 y. After the pulmonary
rehabilitation program, there were fewer, although not statistically significantly different hospital
admissions (2.1 vs 1.7, P  .17). Three years after the pulmonary rehabilitation program, 34
subjects died (36.6%). Hypercapnic respiratory failure (P  .02), noninvasive ventilation (P  .002),
lung cancer (P  .001), shorter 6-min walk distance (P  .03), and higher number of previous
hospital admissions (P < .001) were associated with a higher mortality rate. CONCLUSION: There
is a high mortality rate in late-stage patients with COPD. The most relevant factors associated with
mortality were lung cancer, respiratory failure and noninvasive ventilation, severe exacerbations
with hospitalization, and lower functional exercise capacity. Key words: COPD; pulmonary rehabil-
itation; mortality; functional exercise capacity; lung cancer; respiratory failure; noninvasive ventilation;
exacerbations. [Respir Care 2016;61(9):1179–1185. © 2016 Daedalus Enterprises]
Introduction
COPD is a high-mortality disease, with approximately
2.75 million deaths/y, or 4.8% of all deaths.1 It is projected
to become the third most common cause of death world-
wide by the year 2030.2 In fact, in 2011, COPD was al-
ready the third major cause of death in developed coun-
tries, such as the United States.3
COPD patients usually have respiratory symptoms, such
as dyspnea, chronic cough, or sputum production,4,5 but
also present with systemic manifestations of disease, in-
cluding exercise limitation,6 peripheral muscle impair-
ment,6,7 secondary pulmonary hypertension,8 anemia,9
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malnutrition,10 and exacerbations leading to hospital ad-
missions11 and mortality.12
Pulmonary rehabilitation is, after smoking cessation, un-
doubtedly one of the most important multidisciplinary
global intervention therapies, not only in the management
of respiratory symptoms13 and decreasing dyspnea,14 but
also in improving health status13,15 and exercise capacity,16
ameliorating psychosocial dysfunction,13 and reducing
health-care resource utilization,17,18 namely reducing hos-
pital readmissions and mortality among patients who re-
ceived pulmonary rehabilitation after an exacerbation of
COPD.19,20
It is recognized that individuals with COPD who have
low levels of daily physical activity have higher mortality
rates compared with those who are more physically ac-
tive.21 Therefore, a pulmonary rehabilitation program as-
sumes a fundamental role in the prognosis of these pa-
tients. The long-term survival of patients with chronic
respiratory disease who are referred for pulmonary reha-
bilitation, however, is generally poor, not only because of
severely advanced respiratory disease and the negative im-
pact of exacerbations, but also due to the burden of co-
morbidities.6,16
Based on these associations, we designed a study to
determine predictors of 3-y mortality in advanced stage
COPD subjects who have completed a pulmonary rehabil-
itation program in a day-hospital for chronic respiratory
failure. We also investigated factors associated with early
(1 y) and late mortality (second and third year) and with
fewer hospital admissions after the program.
Methods
We performed an historical cohort study of baseline
characteristics in subjects who completed a pulmonary re-
habilitation program in our day-hospital for chronic respi-
ratory failure, from January 2008 to December 2010.
Inclusion criteria were: diagnosis of COPD according to
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria4 of FEV1/FVC after bronchodilator of
0.70 and completion of a pulmonary rehabilitation pro-
gram.
The pulmonary rehabilitation program had a length of
12–16 weeks and included aerobic exercise training on a
treadmill or a cycle ergometer with a target intensity of at
least 60% of the initial incremental exercise test, large
body muscle strength training, breathing exercises (includ-
ing breathing control and airway clearance techniques),
psychosocial and nutritional support when required, and
an individualized or group self-management educational
program. These sessions included education on the correct
use of respiratory medication and the importance of reg-
ular physical activity and smoking cessation as well as
identification of symptoms and signs of exacerbation.
Subjects were also encouraged to apply a home-exercise
routine (stationary cycle at home or regular walking,
30 min/day, most days of the week) as a way to enhance
activity levels and improve activity of daily living efficacy
during and beyond the pulmonary rehabilitation program.
Regular medical and physiotherapist follow-up was set to
monitor clinical status and the maintenance of physically
active habits.
The population was characterized by sociodemographic
factors: sex, age, working status (active or retired), socio-
economic status (economic insufficiency), and cohabita-
tion (living alone or with cohabitants or institutionalized
patients). The population was also characterized according
to body mass index, smoking habits, lung function tests
(FVC, FEV1, FEV1/FVC, total lung capacity, residual vol-
ume, lung diffusing capacity determined by the single-
breath technique - carbon monoxide transfer coefficient,
respiratory failure, comorbidities, bacterial colonization,
Modified Medical Research Council dyspnea index, func-
tional exercise capacity (6-min walk distance),22 use of
noninvasive ventilation, long-term oxygen therapy, hospi-
tal admissions due to COPD exacerbations 3 y before and
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Current knowledge
COPD is a high-mortality disease with clinical mani-
festations including not only respiratory symptoms but
also systemic manifestations, such as exercise limita-
tion, peripheral muscle impairment, secondary pulmo-
nary hypertension, anemia, malnutrition, and exacerba-
tions leading to hospital admissions. Pulmonary
rehabilitation is one of the most important multidisci-
plinary therapies. Patients with COPD and low levels of
daily physical activity have higher mortality rates com-
pared with patients who are more physically active, but
clinical studies have not identified mortality predictive
factors in patients with severe COPD after pulmonary
rehabilitation.
What this paper contributes to our knowledge
The most relevant factors associated with mortality
found in our study were: lung cancer, respiratory failure
and noninvasive ventilation, atrial fibrillation, severe
exacerbations with hospitalization, and lower functional
exercise capacity. Severe exacerbations predicted mor-
tality. Reducing hospitalizations and improving daily
physical activities should be primary goals in the man-
agement and treatment of patients with COPD. Thus
pulmonary rehabilitation, by enabling these outcomes,
becomes a fundamental multidisciplinary intervention
therapy that should be promptly offered to these patients.
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after the pulmonary rehabilitation program, history of me-
chanical ventilation, and mortality. All subjects’ clinical
data were collected from the medical records.
An exploratory analysis was carried out for all vari-
ables. Categorical data were presented as frequencies
(percentages), and continuous variables were presented
as mean  SD or median (interquartile range), as ap-
propriate.
We analyzed factors associated with early (1-y) and late
(second and third year) all-cause mortality. As a secondary
end point, we also looked for factors associated with fewer
hospital admissions for COPD exacerbation in the 3 y after
completing the pulmonary rehabilitation program.
Inter- and intragroup comparisons were completed us-
ing paired t test for continuous variables and Pearson chi-
square and analysis of variance tests for categorical vari-
ables. Explanatory variables were assessed using binomial
logistic regression. P  .05 was deemed significant. All
data were analyzed using SPSS Statistics version 20.0 for
Windows (IBM, Armonk, New York).
Regarding sample size, several factors were considered.
Data regarding mortality in COPD are scarce and highly
dependent on subjects’ characteristics (age and smoking
habits) and disease severity (FEV1, diffusing capacity of
the lung for carbon monoxide, dyspnea, the presence and
number of exacerbations, comorbidities, PaCO2, and fol-
low-up time); in general COPD subjects, each of these
factors have their own relative risk/hazard ratio, as de-
scribed, for example, by Nishimura et al23; mortality data
regarding patients with severe COPD undergoing pulmo-
nary rehabilitation programs are nonexistent.
Given these conditions, this study ideal (or minimum)
sample size is dependent on the tested variable and
impossible to present as a single value. As an example,
a number based on an extrapolation from data of
mortality/survival and hazard ratio defined for each of
the above variables in a general COPD cohort is differ-
ent in several studies.23,24
Assuming a type-1 error of 0.05 (), a power of 80%,
and an expected 40% mortality rate in our cohort at 3 y,
the number of subjects (N) to be enrolled should be be-
tween 354 (for a variable with a relative risk of 1.4) and 48
(for a variable with a relative risk of 2.6), as computed for
dichotomous variables in PS software 3.0 (Vanderbilt
University, Nashville, Tennessee). The hospital’s ethics
committee and administration board approved the trial
conduction (institutional review board approval
DIRCLIN-22DEZ2014-0430).
Results
Throughout this period, 183 patients were referred to
our unit and completed at least 20 sessions of a pulmo-
nary rehabilitation program. Of this group, 93 subjects
had COPD and were included in our study: 37 subjects
in 2008, 29 subjects in 2009, and 27 subjects in 2010.
Sociodemographic, clinical, and functional characteris-
tics of the subjects are reported in Tables 1 and 2. The vast
majority of our subjects were male (n  78; 83.9%), with
a mean age of 68.6  8.9 y (range 43–85 y) and a mean
body mass index of 25.7  5.8 kg/m2 (range 14.0–49.3).
Most of our subjects were smokers or former smokers
(97.8%) with a mean of 59.9  30.0 pack-years. When
considering economic status, 21 subjects (22.6%) presented
with economic insufficiency. Regarding bacterial coloni-
zation, 20 subjects (21.8%) were colonized with multi-
drug-resistant bacteria.
The mean FEV1 was 37.1  13.7% (range 9–78%), and
mean diffusing capacity (by single-breath technique) was
45.6  21.4% (range 18–108%). Mean functional capac-
ity (6-min walk distance [6MWD]) was 227.7  91.5 m
(range 30–430).
When considering comorbidities, the mean number was
4.98  2.19 (range 0–10)/subject. The most frequent co-
morbidities were cardiovascular: 50 subjects (53.8%) had
arterial hypertension, and 41 subjects (44.1%) had conges-
tive heart failure. The third most frequent comorbidity was
bronchiectasis in 45 subjects (48.4%) (Fig. 1).
During the first year after the pulmonary rehabilitation
program, 16 subjects died, corresponding to an early mor-
tality of 17.2%. During the second year, 6 subjects (6.45%)
died, and 12 subjects (12.9%) died during the third year,
corresponding to a global (3-y) mortality of 34 subjects
(36.6%).
Throughout the 3-y period and analyzing the sub-
jects’ baseline characteristics, hypercapnic respiratory
failure (P  .02), noninvasive ventilation (P  .002),
lung cancer (P  .001), shorter 6MWD (P  .027),
and higher number of previous hospital admissions
(P .001) were all associated with a higher 3-y mortality
rate (see Tables 1 and 2). When comparing early versus
late mortality, the only factor associated with early mor-
tality was atrial fibrillation, although the association
was not statistically significant (P  .050). The number
of comorbidities was not statistically different between
subjects who died and those who were alive 3 y after the
pulmonary rehabilitation program (5.06  2.09 versus
4.93  2.26, P  .79). In the 3-y period after the pul-
monary rehabilitation program, there were fewer hospi-
tal admissions than in the 3 y before, although the dif-
ference was not statistically significant (1.7  2.2 versus
2.1  2.6, P  .17). When performing logistic regres-
sion analysis, previous hospital admissions was the only
variable associated with an increased death risk (rela-
tive risk 1.57 [CI 1.2–2.0], P  .001).
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Discussion
In our study, there was a high mortality (36.6%) in
subjects with COPD in the 3 y after completing a pulmo-
nary rehabilitation program, which might be justified by
the severity of air-flow limitation (mean FEV1 of 37.1%),
with significant dyspnea in daily life activities (median
Modified Medical Research Council dyspnea index 3), and
by a high rate of respiratory failure (n  84; 90.3%).
Although the number of comorbidities was not associated
with mortality, some comorbidities might have contributed
to mortality, such as lung cancer and cardiovascular
diseases. Sex and age, as well as smoking habits, were
not associated with increased mortality, similar to other
studies.25,26
This study also evidenced that throughout the 3-y pe-
riod, hypercapnic respiratory failure (P  .02), noninva-
sive ventilation (P  .002), lung cancer (P  .001), shorter
6MWD (P  .027), and a higher number of admissions
were associated with a higher mortality rate (P  .001).
The presence of respiratory failure and use of noninvasive
ventilation also reflected the severity of the disease.
As demonstrated in previous studies, functional exercise
capacity, in particular 6MWD, is a strong predictor of
Table 1. Sociodemographic and Clinical Characteristics of Subjects With COPD Who Completed a Pulmonary Rehabilitation Program
Characteristics All Subjects Alive Subjects Deceased Subjects n P
Sociodemographic
Male/female sex, n (%) 78/15 (83.9/16.1) 48/11 (52.2/12.0) 30/4 (32.2/4.4) 93 .39
Age, mean  SD y 68.6  8.9 67  10 71  6 93 .10
BMI, mean  SD kg/m2 25.7  5.8 25.8  5.4 25.6  6.4 91 .90
Smoking habits
Smokers, n (%) 11 (11.8) 55 (27) 67 (33) 93
Former smokers, n (%) 80 (86.0) 12 (13.1) 9 (9.8) 93
Never-smokers, n (%) 2 (2.2) 2 (2.3) 1 (1.1) 93
Pack-years, mean  SD 59.9  30.0 34  38.6 51  58.0 93 .053
Economic insufficiency, n (%) 21 (22.6) 1 (1.1) 6 (6.5) 93 .15
Working status, n (%)
Active 3 (3.4) 33 (35.9) 48 (52.1) 88
Retired 85 (96.6) 3 (3.3) 1 (1.1) 88
Cohabitation, n (%)
Alone 7 (7.6) 92
Cohabitants 81 (88.0) 92
Institutionalized 4 (4.4) 92
Clinical characteristics
Comorbidities, n (%)
Arterial hypertension 50 (53.8) 34 (37.0) 16 (17.4) 93 .33
Cardiac failure 41 (44.1) 27 (29.4) 13 (14.1) 93 .67
Cor pulmonale 19 (20.4) 13 (14.1) 6 (6.5) 93 .61
Atrial fibrillation 18 (19.4) 12 (13.0) 6 (6.5) 93 .75
Diabetes mellitus 15 (16.1) 9 (9.8) 6 (6.5) 93 .76
OSA 17 (18.3) 10 (10.9) 7 (7.6) 93 .66
TB sequelae 25 (26.9) 17 (18.5) 8 (8.7) 93 .66
Bronchiectasis 45 (48.4) 29 (31.5) 16 (17.4) 93 .85
Interstitial lung disease 7 (7.5) 5 (5.4) 2 (2.2) 93 .65
Neoplasm 6 (6.5) 0 (0.0) 6 (6.5) 93 .001
Bacterial colonization 20 (21.8) 10 (10.9) 10 (10.9) 93 .10
Respiratory failure, n (%)
Hypoxemic 31 (33.3) 25 (27.2) 6 (6.5) 93
Hypercapnic 53 (57.0) 27 (29.4) 26 (28.3) 93 .02
Long-term oxygen therapy, n (%) 72 (77.4) 45 (48.9) 27 (29.4) 93 .73
NIV, n (%) 28 (30.1) 11 (12.0) 17 (18.5) 93 .002
Previous hospital admissions, median (interquartile range) 1 (0–3) 1 (0–2) 3 (1–5) 93 .001
BMI  body mass index
OSA  obstructive sleep apnea
TB  tuberculosis
NIV  noninvasive ventilation
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mortality in subjects with COPD.16,27 In fact, 6MWD is a
stronger mortality predictor than FEV1,28 in part because it
is also influenced by other factors: cardiovascular perfor-
mance, peripheral muscle function, body composition, and
other comorbidities. The ECLIPSE study29 enrolling a large
number of subjects with COPD (n  2,164) evidenced the
prognostic value of 6MWD in mortality. Spruit et al13
found that a 6MWD threshold of 334 m predicted an in-
creased risk of death. In our study, mean 6MWD was
lower than this cut-off (227.7 m). Bowen et al30 have
demonstrated that variables strongly associated with in-
creased survival following a pulmonary rehabilitation pro-
gram included a higher post-rehabilitation functional ac-
tivities score and higher post-rehabilitation 6MWD. Also,
general daily physical activity (eg, standard walking) has
proven to be beneficial for these patients, reducing hospi-
tal admissions and global mortality.31
Pulmonary rehabilitation in all stages of COPD is an
effective and important therapy to improve exercise toler-
ance, muscle strength, and quality of life and decrease
respiratory symptoms. Therefore, it should be provided to
all symptomatic patients with COPD. It is also fundamen-
tal to refer patients with COPD as early as possible (avoid-
ing referral only when patients reach advanced stage dis-
ease) in order to improve functional capacity and to further
stimulate regular physical activity.
A logistic regression model analysis confirmed that pre-
vious hospital admissions was associated with an increased
Table 2. Functional Characteristics Associated With 3-Year Mortality in Subjects With COPD After a Pulmonary Rehabilitation Program
Functional Characteristics All Subjects Alive Subjects Deceased Subjects n P
FEV1, mean  SD L 0.9  0.3 1.0  0.3 0.9  0.3 89 .16
FEV1, mean  SD % 37.1  13.7 38  14 35  14 93 .19
FVC, mean  SD L 2.2  0.7 2.3  0.7 2.0  0.7 90 .16
FVC, mean  SD % 69.7  21.9 71  21 67  23 92 .49
TLC, mean  SD L 6.6  1.6 6.6  1.6 6.4  1.5 60 .73
TLC, mean  SD % 111.3  21.0 110  23 114  16 64 .43
RV, mean  SD L 4.3  1.3 4.3  1.4 4.2  0.8 62 .95
RV, mean  SD % 180.5  51.9 178  60 184  27 68 .56
DLCO, mean  SD % 45.6  21.4 46  21 46  24 57 .99
KCO, mean  SD % 51.7  22.7 51  22 55  27 54 .55
MMRC, median (interquartile range) 3.0 (2–4)
6MWD, mean  SD m 227.7  91.5 243  91 198  87 89 .03
SpO2 (6MWT) 90%, n (%) 61 (65.6) 39 (42.4) 21 (22.8) 81 .25
TLC  total lung capacity
RV  residual volume
DLCO  lung diffusing capacity determined by the single-breath technique
KCO  carbon monoxide transfer coefficient
MMRC  Modified Medical Research Council dyspnea scale
6MWD  6-min walk distance
6MWT SpO2 90%  6-min walk test with oxygen saturation 90%
Fig. 1. Comorbidities in subjects with COPD after pulmonary rehabilitation. Arterial HTN  arterial hypertension, CHF  congestive heart
failure, OSAHS  obstructive sleep apnea-hypopnea syndrome, TB sequelae  tuberculosis sequelae, ILD  interstitial lung disease.
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death risk (relative risk 1.57, P  .001) in the 3 y after the
program.
Exacerbations of COPD are associated with a lower
quality of life and are a risk factor for increased mortal-
ity11,32; therefore, reducing the number of hospitalizations
is a priority in the management of these patients.13 In our
study, there were fewer admissions in the 3-y period fol-
lowing the pulmonary rehabilitation program, yet this did
not reach statistical significance (1.7  2.2 versus
2.1  2.6, P  .17), similar to what happened in other
studies.17,18 This could be explained by the fact that sub-
jects included in our study had severe air-flow obstruction
and therefore had, in general, more hospital admissions. In
deceased subjects, the only factor associated with early
mortality was atrial fibrillation, although this association
was not statistically significant (P  .050).
COPD has been associated with an increased prevalence
of lung cancer, osteoporosis, anemia, coronary heart dis-
ease, anxiety, and depression.6 In fact, COPD is associated
with a high prevalence of comorbidities. In a study by
Areias et al,33 97% subjects with GOLD stage IV COPD
presented with at least one comorbidity, with an average of
4 comorbidities/subject. In another study from our group,34
114 subjects with COPD who attended a pulmonary reha-
bilitation program had the same high percentage of co-
morbidities (96.5%). Divo et al8 evaluated 1,664 subjects
for 51 months, recording their comorbidities. They devel-
oped a graphic representation system of the prevalence
and strength of association with mortality in the form of a
“comorbidome.” These authors found an average number
of comorbidities of 6, and 58.9% of subjects had at least
one cardiovascular comorbidity. In their study, atrial
fibrillation/flutter had a strong association with increased
risk for death (HR 1.56, P  .001). Cardiovascular dis-
ease, therefore, plays a fundamental role in mortality of
patients with COPD,8,33 and our study reflected the higher
prevalence of such comorbidities, namely arterial hyper-
tension and congestive heart failure.
Identification and control of risk factors, such as smok-
ing, is a key factor for COPD, lung cancer, and cardio-
vascular comorbidity management and might have an im-
pact on long-term outcomes, including survival. As
demonstrated by Bowen et al,30 the 2 functional status
indicators, 6MWD and the functional activity subscore,
were the strongest predictors of post-rehabilitation sur-
vival; therefore, pulmonary rehabilitation and an increase
in patients’ daily physical activity should be encouraged.
This study’s limitations include the retrospective nature
of the historical cohort, not allowing for control of all
variables in the sample of subjects, and the possible pres-
ence of unidentified confounders. Regarding sample size,
although we recognize that our cohort size (n  92) is
suboptimal to test variables with a weak association with
mortality, it is (and in fact was) enough to test variables
strongly associated with mortality. Second, the study pop-
ulation is restricted to subjects attending a pulmonary re-
habilitation program in a day-hospital for chronic respira-
tory failure. Therefore, the findings are only applicable to
that group of severe subjects, and we cannot generalize our
results to all patients with COPD. Also, the referral of
subjects to a pulmonary rehabilitation program could re-
sult in a referred bias toward subjects with a greater degree
of limitations or symptoms. Third, there was a high prev-
alence of males, so we cannot extend conclusions to the
female sex.
Conclusions
There was a high mortality rate in subjects with late-
stage COPD who underwent a pulmonary rehabilitation
program, the most relevant factors associated with mor-
tality being lung cancer, respiratory failure and noninva-
sive ventilation, severe exacerbations with hospitalization,
and lower functional exercise capacity. Pulmonary reha-
bilitation program plays a fundamental role by increasing
patients’ daily physical activity, reducing hospital admis-
sions and global mortality. Also the management of these
patients’ multiple comorbidities might have an impact on
long-term outcomes, including survival.
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mark E. Subjects with COPD and productive cough have an in-
creased risk for exacerbations and death. Respir Med 2015;109(1):
88-95.
6. Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert
C, Marchand-Adam S, et al. Comorbidities of COPD. Eur Respir
Rev 2013;22(130):454-475.
7. Mador MJ, Deniz O, Aggarwal A, Kufel TJ. Quadriceps fatigability
after single muscle exercise in patients with chronic obstructive pul-
monary disease. Am J Respir Crit Care Med 2003;168(1):102-108.
8. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata
V, et al. Comorbidities and risk of mortality in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2012;
186(2):155-161.
9. Similowski T, Agustı́ A, MacNee W, Schönhofer B. The potential
impact of anaemia of chronic disease in COPD. Eur Respir J 2006;
27(2):390-396.
10. Cote CG. Surrogates of mortality in chronic obstructive pulmonary
disease. Am J Med 2006;119(10 Suppl 1):54-62.
PREDICTIVE FACTORS FOR MORTALITY IN COPD
1184 RESPIRATORY CARE • SEPTEMBER 2016 VOL 61 NO 9
11. Marchetti N, Criner GJ, Albert RK. Preventing acute exacerbations
and hospital admissions in COPD. Chest 2013;143(5):1444-1454.
12. Quintana JM, Esteban C, Unzurrunzaga A, Garcia-Gutierrez S, Gon-
zalez N, Barrio I, et al. Predictive score for mortality in patients with
COPD exacerbations attending hospital emergency departments.
BMC Med 2014;12:66.
13. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C,
et al. An official American Thoracic Society/European Respiratory
Society statement: key concepts and advances in pulmonary reha-
bilitation. Am J Respir Crit Care Med 2013;188(8):e13–e64.
14. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y.
Pulmonary rehabilitation for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev 2015;(2):CD003793.
15. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Pérez-
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